1 Mast cells derive from the bone marrow and are responsible for the development of allergic and possibly in¯ammatory reactions. Mast cells are stimulated by immunoglobulin E (IgE) and speci®c antigen, but also by a number of neuropeptides such as neurotensin (NT), somatostatin or substance P (SP), to secrete numerous pro-in¯ammatory molecules that include histamine, cytokines and proteolytic enzymes. 2 Chondroitin sulphate, a major constituent of connective tissues and of mast cell secretory granules, had a dose-dependent inhibitory eect on rat peritoneal mast cell release of histamine induced by the mast cell secretagogue compound 48/80 (48/80). This inhibition was stronger than that of the clinically available mast cell`stabilizer' disodium cromoglycate (cromolyn). Inhibition by chondroitin sulphate increased with the length of preincubation and persisted after the drug was washed o, while the eect of cromolyn was limited by rapid tachyphylaxis. 3 Immunologic stimulation of histamine secretion from rat connective tissue mast cells (CTMC) was also inhibited, but this eect was weaker in umbilical cord-derived human mast cells and was absent in rat basophilic leukemia (RBL) cells which are considered homologous to mucosal mast cells (MMC). Oligo-and monosaccharides were not as eective as the polysaccharides. 4 Inhibition, documented by light and electron microscopy, involved a decrease of intracellular calcium ion levels shown by confocal microscopy and image analysis. Autoradiography at the ultrastructural level showed that chondroitin sulphate was mostly associated with plasma and perigranular membranes.
Introduction
Mast cells derive from the bone marrow and migrate into connective and mucosal tissues (Galli, 1993) , where they are located at strategic points around capillaries close to nerve endings (Theoharides, 1996) . Mast cells are critical for allergic reactions where the stimulus is immunoglobulin E (IgE) and speci®c antigen; however, there are also other nonimmune mast cell triggers that include anaphylatoxins, kinins, cytokines, as well as various neuropeptides (Baxter & Adamik, 1978; Coey, 1973) such as somatostatin (Theoharides & Douglas, 1978) , neurotensin (NT) (Carraway et al., 1982) and substance P (SP) (Fewtrell et al., 1982) . When stimulated, mast cells synthesize and secrete numerous vasoactive, nociceptive and in¯amma-tory mediators (Galli, 1993 ) that include histamine, kinins, prostaglandins, leukotrienes, cytokines, as well as the proteolytic enzymes chymase and tryptase (Schwartz, 1987) . Such evidence has implicated mast cells also in in¯ammatory conditions (Galli, 1993; Theoharides, 1996) . Sulphated proteoglycans constitute the major constituents of mast cell secretory granules. Of these, heparin is mostly found in connective tissue mast cells (CTMC), while chondroitin sulphate in MMC (Seldin et al., 1985b; Razin et al., 1983) . Recent evidence indicates that chondroitin sulphate is also present in human connective tissue (Krilis et al., 1992) and umbilical cord-derived human mast cells (Blom et al., 1996) .
A number of compounds have been reported to block rat mast cell secretion experimentally. These include the lodoxomides (Johnson, 1980) , doxantrazole (Pearce et al., 1982; Fox et al., 1988) , quercetin (Fox et al., 1988; Fewtrell & Gomperts, 1977) and certain histamine-1 receptor antagonists such as hydroxyzine (Theoharides et al., 1985; Fischer et al., 1995) and ketotifen (Nemeth et al., 1987) . The only clinically available`anti-allergic' drugs are cromolyn (Orr et al., 1971) and its structurally related nedocromil (EnerbaÈ ck & BergstroÈ m, 1989 ); yet, they are not capable of eectively blocking human mast cell secretion (Okayama et al., 1992) . In addition, the inhibitory action of these drugs is short-lived due to the induction of tachyphylaxis (Theoharides et al., 1980) and they do not inhibit mucosal mast cells (MMC) (Barrett & Metcalfe, 1985; Pearce et al., 1982; Fox et al., 1988) . Among mast cell derived molecules, histamine has an autoinhibitory action only in the brain through activation of histamine-3 receptors (Rozniecki et al., 1999) , while arachidonic acid products have variable and weak inhibitory eects (Theoharides, 1990) . We hypothesized that chondroitin sulphate released from in¯amed tissue, as well as from mast cells, could have an inhibitory eect on mast cell secretion. Here we show that chondroitin sulphate is a potent inhibitor of histamine release from CTMC.
Methods

Mast cell purification and treatment
Peritoneal mast cells were isolated from male (250 ± 300 g) Sprague Dawley rats (Jackson Labs, Bar Harbor, ME, U.S.A.) using Locke's solution (mM: NaCl 150, KC1 5, HEPES 5, CaC1 2 2, 0.1% bovine serum albumin, 0.1% Dextrose, pH 7.2) and were puri®ed (495%) by centrifugation through 22.5% Metrizamide (Accurate Chemical & Scienti®c Corp., Westbury, NY, U.S.A.) (Theoharides et al., 1982) ; the remaining cells were lymphocytes and a few macrophages. The cell pellet was washed and resuspended (10 5 
Culture of RBL cells
The rat basophilic leukaemia (RBL) cells are considered homologous to rat mucosal mast cells (Seldin et al., 1985a) . They were kindly provided by Dr Henry Metzger (NIH) and were grown as described previously (Isersky et al., 1975) .
Isolation and culture of umbilical cord-derived human mast cells
Human umbilical cord blood samples were obtained from normal full-term deliveries under the approval from the Human Investigation Review Board. Cord blood was collected in tubes containing 10 U ml 71 heparin and was diluted with twice the volume of phosphate-buered saline (PBS). Mast cell progenitors were separated as described before (Kempuraj et al., 1999) . Mononuclear cells were separated by density-gradient centrifugation using Lymphocyte Separation Medium (LSM; Organon Teknika Corp, Durham, NC, U.S.A.). The interface containing mononuclear cells was collected and CD34 + cells were separated using a magnetic separation column according to the manufacturer's instructions (Macs II, Miltenyl Biotec, Bergisch Gladbach, Germany) . Magnetic microbeads were removed with the CD34 + isolation kit (Miltenyl Biotec). The CD34 + cells were further separated with mouse anti-CD34 antibody followed by antimouse IgG1 magnetic microbeads (Miltenyl Biotec). The CD34 + cells were cultured in Iscove's Modi®ed Dulbecco's Medium (Gibco BRL, Grand Island, NY, U.S.A.) supplemented with 10% FBS, 100 ng 71 ml human stem cell factor (SCF) from Amgen (Thousand Oaks, CA, U.S.A.) and 50 ng ml 71 IL-6 (Atlanta Biologicals, Norcross, GA, U.S.A.) in 75-cm 2¯a sks at 378C in 5% CO 2 , for greater than 10 weeks (Kinoshita et al., 1999) .
Immunologic stimulation of mast cells
Unpuri®ed rat peritoneal mast cells (10 6 ml
71
) were ®rst incubated with 1.5 mg/10 5 cells ml 71 rat IgE (Zymed, So. San Francisco, CA, U.S.A.) for 30 min in order to occupy the respective receptors to protect them from destruction during the puri®cation step (Coutts et al., 1980) (Trnovsky et al., 1993) . After 48 h, cells were washed twice with PBS and sensitized for 24 h with 1.0 mg ml 71 of rat monoclonal IgE to dinitrophenol (DNP) (Zymed). Cells were washed twice with PBS and stimulated with 50 ng ml For histamine secretion the supernatant and the cell pellet, to which an equal volume of Locke's or Tyrode's solution had been added, were acidi®ed with 20% perchloric acid. Following freezing and boiling for 5 min, both supernatant and pellet were centrifuged at 17,0006g for 5 min to remove denatured protein, and histamine was assayed¯uorometri-cally (Theoharides et al., 1982) . The results are expressed as (supernatant/supernatant+pellet) 6100. The data for each incubation time and condition are expressed as mean+ standard error of the mean (s.e.mean) and statistical analysis was performed using ANOVA.
Intracellular calcium measurement
Mast cells (10 6 ml 71 ) were incubated with 5 mg/ml of crimson calcium AM cell permeant probe (Cat. No. C-3018, Molecular Probes, Eugene, OR, U.S.A.) for 5 min at 378C in Locke's solution without calcium and 0.1 mM EDTA. This indicator dye has been used eectively to measure intracellular calcium ion levels (Scheenen et al., 1998; Herman, 1997; June & Rabinovitch, 1994) . Mast cells were washed and resuspended in Locke's solution without calcium and 0.1 mM EDTA. Mast cells (180 ml) were then incubated with 0.1 mg ml 71 compound 48/80 with or without preincubation with chondroitin sulphate for 10 min at room temperature in an open topped Sykes-Moore chamber. They were examined with a Confocal Laser Scanning Imaging System Odyssey XL (Norans Instruments) equipped with a Crypton-Argon laser set at 560l (42% intensity) and attached to a Silicon Graphics computer. For image analysis, a ®eld of cells (usually six to 10) was selected. Photography was started taking one frame every 20 s immediately after the addition of the study drug or the secretagogue (20 ml) for 10 min. Image analysis was performed using Image Pro Plus imaging software (Media Cibernetics, 8484 Georgia Avenue, Silver Springs, MD, U.S.A.). Each cell was analysed separately. Final magni®cation of 6006 was used. Fifteen photographic images for each sample were printed on one 8610 sheet of photographic paper and the images were subsequently digitized for analysis. First, a low threshold was established that extinguished the last image pixel. Thereafter, and at time points through 10 min, pixel values were recorded in response to drug treatment. The illuminated pixel values, representing areas, were then read from the program and plotted on graph paper.
Microscopy
For light microscopy, the cells were ®xed with 4% paraformaldehyde in PBS for 30 min at room temperature. The cells were then washed with PBS, aliquoted onto slides and stored at 7208C for further analysis. For electron microscopy, after immersion ®xation of the cell pellet in 2.5% glutaraldehyde, the samples were washed in PBS, post-®xed in 2% osmium tetroxide, dehydrated in graded ethanol solutions and embedded in Epon. Semi-thin sections (0.5 mm) were stained with toluidine blue, while ultrathin sections (1000 A) were contrasted in 7.5% uranyl acetate in 50% ethanol and 0.1% aqueous lead citrate. Grids with the sections were examined and photographed using a Phillips CM-10 transmission electron microscope. For autoradiography, chondroitin sulphate was custom-tritiated at New England Nuclear (Boston, MA, U.S.A.) and was made available at speci®c activity of 4.3 mCi ml
71
; 10 5 mast cells were incubated with 2.5 mCi 3 H-chondroitin sulphate for 30 min at 378C. The cells were then washed twice, ®xed and processed for autoradiography at the ultrastructural level without the uranyl acetate step; they were stained with lead citrate for 7.5 min (instead of 3 min when uranyl acetate is present). The cells were then examined and photographed using a Phillips-CM-10 transmission electron microscope; exposure was carried out for 7 days at 48C.
Results
Histamine release from rat CTMC stimulated with 0.1 mg ml 71 of the classic mast cell secretagogue compound 48/80 (48/80) was 22.1+1.3% (n=19). Preincubation with chondroitin sulphate resulted in inhibition of histamine release in response to 48/80 (0.1 mg ml 71 used for 30 min at 378C); inhibition increased with time and reached a maximum of 76.5% (P=0.0004) by 10 min ( Figure 1A ). In contrast, the inhibitory action of cromolyn decreased rapidly if preincubation lasted for more than 1 min ( Figure 1A ). We then investigated whether this inhibitory eect may had been due to some electrostatic interaction between the negatively charged chondroitin sulphate and the cationic 48/80, leading to neutralization of the latter. Following incubation with 10 75 M chondroitin sulphate for 10 min at 378C, mast cells were washed up to ®ve times before stimulation with 0.1 mg ml 71 48/80; the extent of inhibition was not diminished by the washes (results not shown). We also investigated how long the inhibitory activity of chondroitin sulphate lasted after two washes. Mast cells were incubated with 10 75 M chondroitin sulphate for 10 min at 378C, washed twice in Locke's solution and then stimulated by 0.1 mg ml 71 48/80 either immediately after or at 5, 15, 30, 60 and 120 min after the wash; there was no statistically signi®cant reduction of the inhibitory eect even when 48/80 was added 2 h later (results not shown).
Pre-incubation with chondroitin sulphate for 10 min at 378C inhibited histamine release in a dose-dependent manner ( Figure 1B ). The inhibitory eect of chondroitin sulphate was comparable to that of cromolyn, but chondroitin sulphate was more potent at the highest concentrations. Maximal inhibition of 76% (P=0.0004) was seen at 10 74 M when histamine release decreased from 22.0+1.3% (n=19) to 5.7+0.6% (n=13). At 10 75 M (n=6), histamine decreased to 11.2+1.4% (49.4% inhibition, P50.05) and at 10 76 M (n=6), it decreased to 18.2+1.3% (17.3% inhibition, P50.05). There was only 9.4% inhibition at 10 77 M (n=7) with histamine release at 19.9+2.4% which was borderline signi®cant. At 10 78 M (n=4), there was no inhibition and histamine release was 20.8+2.6% (P40.05).
The inhibitory eect of chondroitin sulphate extended to stimulation of rat CTMC by the neuropeptide SP, as well as by immunoglobulin E and anti-IgE; this inhibition also showed a dose-response relationship ( In order to study the size or charge requirement of chondroitin sulphate, we compared its inhibitory action at 10 75 M on immunologic stimulation of rat CTMC to that of high (HMW) and low molecular weight (LMW) heparin, as well as chondroitin sulphate disaccharide, and the monosaccharides D-glucosamine sulphate and N-acetyl-glucosamine (10 74 M). They were all weaker inhibitors than chondroitin sulphate (Table 2 ). For instance, chondroitin sulphate disaccharide inhibited immunologically stimulated histamine release by 23.6%, as compared to equimolar concentrations of the parent molecule ( Table 2 ). The monosaccharides D-glucosamine sulphate and N-acetylglucosamine inhibited histamine release by 20.0 and 24.6%, respectively. Finally, HMW heparin was weaker than chondroitin sulphate with 25.5% inhibition, while LMW heparin inhibited histamine release only by 10.3% (Figure 2) . Thus, it appeared that the size and degree of sulphation are important.
We also examined the morphologic appearance of rat CTMC treated with chondroitin sulphate. Control (untreated) mast cells and those preincubated with 10 74 M chondroitin sulphate for 10 min at 378C were intact ( Figure  2A Figure 2C,D) . The possibility that the mechanism of action of chondroitin sulphate may be mediated through an eect on the availability of intracellular calcium ions was then investigated. Mast cells were loaded with the calcium indicator dye crimson red in the absence of extracellular calcium, were washed and observed in Locke's solution using a confocal microscope. Stimulation of secretion by 0.1 mg ml 71 48/80 at room temperature led to a gradual increase in intracellular calcium ion levels shown in 20 s frames over a 10 min period ( Figure 3A) . Preincubation with 10 74 M chondroitin sulphate for 10 min at 378C prior to stimulation with 48/80 at room temperature inhibited calcium ion levels signi®cantly (compare Figure 3A,B) . The extent of the inhibitory eect on intracellular calcium ion levels was con®rmed with image analysis. Preincubation with chondroitin sulphate (10 74 M) decreased the number of pixels from 1376.7+28.1 (n=9) illuminated 10 min after addition of (Table 3) .
The inhibitory eect of chondroitin sulphate was also con®rmed by transmission electron microscopy. Ultrastructural observations showed most control mast cells ( Figure  4A ) and those treated with 10 74 M chondroitin sulphate for 10 min at 378C ( Figure 4B ) to contain intact, homogenous electron dense granules. In contrast, mast cells stimulated by 0.1 mg ml 71 48/80 had undergone extensive degranulation and had lost the electron dense content of most of their secretory granules ( Figure 4C ). Mast cells incubated with 10 74 M chondroitin sulphate for 10 min at 378C before stimulation with 0.1 mg ml 71 48/80 also contained mostly intact electron dense granules ( Figure 4D ). The possible site of action of chondroitin sulphate was investigated by using tritiated chondroitin sulphate. Autoradiography at the ultrastructural level showed that, after a 30 min incubation, 3 H-chondroitin sulphate radioactivity could not be removed even by ®ve washes and was mostly associated with the mast cell surface and perigranular membranes (Figures 5 and 6 ). It is interesting to note that 3 H-chondroitin sulphate-related radioactivity appeared to be least associated with the nucleus or secretory granules that had undergone exocytosis ( Figures  5B and 6) .
We then investigated if the inhibitory eect of chondroitin sulphate was limited only to rat CTMC. For that reason, we tested it against immunologic stimulation of RBL and human cultured mast cells. While chondroitin sulphate (10 75 M) inhibited immunologic histamine release from rat CTMC by 22% (Table 4) , it had no eect (9.4% inhibition, P40.05) on histamine release from RBL cells which are homologous to rat MMC (Table 4 ). Histamine release from umbilical cordderived human mast cells was decreased (Table 4) 
Discussion
The present results show that chondroitin sulphate is a potent inhibitor of mast cell secretion. Chondroitin sulphate is a natural constituent of connective tissues (Hardingham, 1986) , especially cartilage (Lindahl & Hook, 1978) . Chondroitin sulphate is also present in both rat MMC (Seldin et al., 1985b; Razin et al., 1983) and basophils (Orenstein et al., 1978; Reilly et al., 1988; Seldin et al., 1985b; Metcalfe et al., 1984) , as well as in human CTMC (Krilis et al., 1992) and umbilical cord-derived human mast cells (Blom et al., 1996) . The inhibitory action of chondroitin sulphate on histamine release was more potent than of the`antiallergic' drug cromolyn, especially at higher concentrations. Heparin, the structure of which is quite similar to that of chondroitin sulphate and is also stored in mast cells, had been shown to inhibit in vivo release of histamine (Dragstedt et al., 1942) , the immediate response to antigen in the skin and lungs of allergic subjects (Bowler et al., 1993) , as well as bronchoconstriction in exercise-induced asthma (Ahmed et al., 1993a) . Heparin was also shown to prevent allergic airway hyperresponsiveness (Ahmed et al., 1994) and to have a protective eect on immunologic and non-immunologic tracheal smooth muscle contraction in vitro (Abraham et al., 1996; Ahmed et al., 1992) . In fact, just as cromolyn and chondroitin sulphate appear to have roughly equivalent inhibitory activity on CTMC secretion, heparin and the cromolyn analogue nedocromil both induced inhibition of about 50% (Abraham et al., 1996) on tracheal smooth muscle contraction.
While the inhibition by cromolyn disappeared with preincubation times of more than 1 min, the inhibitory action of chondroitin sulphate started at 1 min and progressively increased over 30 min. It was previously shown that the inhibitory action of intravenous heparin in the immediate cutaneous reaction in allergic sheep was enhanced by 60% when the duration of pretreatment was increased from 20 to 60 min (Ahmed et al., 1993b) . Like our ®ndings showing that chondroitin sulphate inhibits both 48/80-induced and immunologic stimulation of mast cells, heparin had been shown to inhibit similar responses in isolated human uterine mast cells (Lucio et al., 1992) . It was somewhat surprising that the inhibitory eect of chondroitin sulphate was more potent for histamine release induced by 48/80 than with SP, since both are thought to occur through the same mechanism (Mousli et al., 1990) . One possible explanation may be the fact that in the absence of extracellular calcium ions, the eect of 48/80 is much weaker than that of SP (Erjavec et al., 1981) , suggesting that the stronger the response the weaker the inhibition; our preliminary results using less SP appear to support this explanation.
Our ultrastructural observations showed that chondroitin sulphate prevented mast cell degranulation. Moreover, auto- Chondroitin sulphate inhibits connective tissue mast cells T.C. Theoharides et alradiographic images suggest that chondroitin sulphate is mostly associated with the mast cell surface and the secretory granule membranes, while largely sparing the nucleus and granules that had undergone exocytosis. Similar ®ndings had been reported in studies of 35 S-chondroitin sulphate uptake in other cultured cells where chondroitin sulphate ®rst interacted with the cell surface and by 2 h was found mostly intracellularly (Saito & Uzman, 1971c) . Our results showed that the plasma membrane and the extruded secretory granules are preferentially¯uorescent in our confocal microscopic images. This is in part due to the fact that the confocal microscope focuses on the surface of live cells. Even with conventional microscopy, however, the plasma membrane of cells in their resting state is preferentially stained for calcium ions (Tasaka et al., 1986; Monck et al., 1992) . Previous reports using Quin-2 or Fura-2 (Penner et al., 1988; Tasaka et al., 1986; Almers & Neher, 1985; Monck et al., 1992) also showed that during stimulation of secretion, there is an increase in calcium ions associated with extruded secretory granules, possibly due to indicator dye trapped inside the granules¯uorescing upon binding extracellular calcium (Almers & Neher, 1985) . There is also binding of the cationic extracellular calcium to the negatively charged extruded granule proteoglycans that permits the intense granule-associated¯uorescence. Real time sequence of 20 s frames showed the gradual increase of intracellular calcium upon stimulation of mast cells with 48/80 and its inhibition by chondroitin sulphate. In these frames, not only the timedependent increase is appreciated, but the cells act as their own controls before stimulation. The precise mechanism through which chondroitin sulphate inhibits mast cell secretion is not entirely clear. Our results indicate the interaction of chondroitin sulphate with mast cells somehow led to inhibition of intracellular free calcium ion levels. This action could not be through a calcium ion channel as 48/80 is known to induce secretion utilizing intracellular calcium (Theoharides et al., 1982) and SP stimulates mast cells in the absence of extracellular calcium (Erjavec et al., 1981) . Heparin had previously been reported to inhibit inositol triphosphateinduced intracellular calcium release from permeabilized rat liver cells (Hill et al., 1987) .
We also do not know whether the inhibitory eect of chondroitin sulphate is mediated through its surface binding and/or some action on the perigranular membrane or both. However, it is interesting to note that mast cell treatment with neuraminidase prevented histamine release induced by SP (Cocchiara et al., 1997) , implying that incorporation of chondroitin sulphate in the plasma membrane may interfere with activation, especially by neuropeptides. How chondroitin sulphate gets across the cell membrane can only be theorized at the present, but a number of publications have shown internalization of both chondroitin sulphate (Saito & Uzman, 1971a,b,c) and heparin (Letourneur et al., 1995a,b) by active uptake through receptor-mediated endocytosis.
Proteoglycans liberated from activated mast cells and/or connective tissues could act as natural inhibitors of mast cell secretion, thus also reducing the extent of local in¯ammation. The mechanism of inhibitory action of chondroitin sulphate may be through two dierent mechanisms. Firstly, competition of compound 48/80 or SP binding to surface proteoglycans through membrane incorporation so that it can not be washed o; for instance, neuraminidase-treated rat peritoneal mast cells could not be stimulated by 48/80 or SP (Mousli et al., 1989) and lectins speci®c for N-acetyl galactosamine and N-acetyl glucosamine oligomers blocked stimulation by 48/80 (Matsuda et al., 1994) . Secondly, chondroitin sulphate may interfere with the action of inositol triphosphate and subsequent increases in intracellular calcium ions, especially since heparin has been shown to act as a competitive inhibitor of inositol triphosphate receptors (Kobayashi et al., 1988; Ahmed et al., 1994) .
Chondroitin sulphate may have additional actions leading to inhibition of in¯ammatory responses in vivo. Since proteoglycans have been shown to extend the life of growth factors (Brittis et al., 1992; Nurcombe et al., 1993; Kan et al., 1993) , exogenously provided chondroitin sulphate may act as a decoy to prevent or limit the action of growth factors on local immune cells or neurons. The possibility that any growth or other factors bound to chondroitin sulphate may have contributed to the inhibitory action of chondroitin sulphate in our experiments is rendered unlikely due to the fact that in certain experiments chondroitin sulphate was ®rst dissolved in high salt to disrupt any loose interactions; it was then ®ltered through a 50 K exclusion ®lter which would have allowed any smaller molecules to be washed through. An additional possible bene®cial eect of chondroitin sulphate in reducing in¯ammation would be its ability to bind intercellular adhesion molecules (Nelson et al., 1993) , often expressed in response to TNF-a released from mast cells (Gordon et al., 1990; Walsh et al., 1991) , and to neutralize proteolytic enzymes released during in¯ammatory responses (Zehnder & Galli, 1999; Humphries et al., 1999; Forsberg et al., 1999) . It is interesting to note that heparin sulphate was recently shown to bind to CD48 (Ianelli et al., 1998) , a molecule that is upregulated in various autoimmune disorders. Such ®ndings are provocative in view of the fact that mast cells are increasingly implicated in in¯ammatory processes (Galli, 1993) especially those exacerbated by stress (Theoharides, 1996) . For instance, mast cells have been implicated in sterile in¯ammatory disorders such as asthma (Barnes, 1988; Lewis & Austen, 1977) , irritable bowel syndrome (Weston et al., 1993) and interstitial cystitis in the urinary bladder (Theoharides et al., 1998) , in all of which a de®cit of glycosaminoglycans has been reported Hurst et al., 1996; Burton & Anderson, 1983) .
A number of non-mast cell natural or synthetic compounds have been reported to inhibit mast cell secretion. These include lodoxamides (Johnson, 1980) , doxantrozole (Pearce et al., 1982; Fox et al., 1988) , quercetin (Fewtrell & Gomperts, 1977; Fox et al., 1988) and certain antihistamines such as hydroxyzine (Theoharides et al., 1985; Fischer et al., 1995) and ketotifen (Nemeth et al., 1987) . Glucocorticoids do not aect anaphylactic mast cell degranulation, but prolonged treatment inhibits the synthesis of arachidonic acid products such as prostaglandins, thromboxanes and leukotrienes in response to immunologic stimulation (Robin et al., 1985; Marquardt & Wasserman, 1983) . On the contrary, even overnight steroid treatment of mast cells did not aect either histamine or arachidonic acid release induced by 48/80 or somatostatin (Heiman & Crews, 1984) . Cromolyn and its structurally related nedocromil known as mast cell stabilizers' (Theoharides et al., 1980) , are available for allergic conjunctivitis, rhinitis, asthma and food allergies (EnerbaÈ ck & BergstroÈ m, 1989; Theoharides et al., 1980; Okayama et al., 1992) , even though they do not appear to be able to inhibit human mast cells (Okayama et al., 1992) , as also shown herein. Moreover, their inhibitory action on histamine release is only modest, short-lived and does not inhibit histamine secretion from MMC (Barrett & Metcalfe, 1985; Pearce et al., 1982; Fox et al., 1988) . Nevertheless, cromolyn was shown to inhibit tumour necrosis-a (TNF-a) release from both CTMC and MMC, an action that required 2 h pretreatment (Bissonnette et al., 1995) . It is interesting that low molecular weight (LMW) heparin preferentially inhibited TNF-a and IL-4 production without aecting degranulation (Baram et al., 1997) . Our preliminary results show that LMW heparin, as well as chondroitin sulphate disaccharide and related monosaccharides are weaker inhibitors of histamine secretion. Weak inhibition on mast cell secretion, has previously been reported for other mast cell derived molecules (Theoharides, 1990 ) such as lipoxins (Conti et al., 1992) , histamine through H-3 receptors in the brain (Rozniecki et al., 1999) and interleukin-8 (Kuna et al., 1991) . Inhibition of mast cell production of nitric oxide (NO) enhanced histamine release in response to compound 48/80 and SP (Brooks et al., 1999) , but diminished mast cell dependent TNF-a-mediated cytotoxicity (Bissonnette et al., 1991) . Both the constitutive and the antigen-induced NO production was inhibited by IL-10; however, long-term (24 h) incubation with IL-10 enhanced histamine release from CTMC (Lin & Befus, 1997) . These ®ndings imply that there may be dierential inhibition of release of mast cell mediators we ®rst reported for biogenic amines (Theoharides et al., 1982) . A number of subsequent reports con®rmed our original observation. For instance, vasoactive amines were dierentially released in T-cell-dependent, as compared to IgE-dependent hypersensitivity reactions (Van Loveren et al., 1984) . Dierential release of histamine without prostaglandin D 2 was reported by peptides (LeviSchaer & Shalit, 1989) and 48/80 (van Haaster et al., 1995) , which also released almost no leukotriene C4 . The anaphylatoxin C5a induced high histamine release without any leukotrienes from human basophils (Dahinden et al., 1989) . Interleukin-10 stimulated IL-6 and TNF-a production without aecting histamine release (Marshall et al., 1996) , while the phosphatidyl-inositol 3-kinase inhibitor Wortmannin inhibited mast cell exocytosis, but not IL-6 production (Marquardt et al., 1996) . Stimulation with SCF resulted in IL-6 release without histamine or leukotriene C4 (Gagari et al., 1997) and bacterial lipopolysaccharide induced release of IL-6 without histamine (Leal-Berumen et al., 1994) .
Dierential activation of mast cells may also vary due to their content, source, as well as experimental or pathological conditions. In addition to the well-known dierences in human protease content (Schwartz, 1987) , human mast cells also dier in their proteoglycan (Pipkorn et al., 1988) and cytokine (Bradding et al., 1995) content. The secretory responsiveness of mast cells also varies considerably. Human mast cells appear capable of constitutively releasing histamine without tryptase (Granerus et al., 1994) . MMC do not secrete in response to 48/80 or neuropeptides (Barrett & Metcalfe, 1985; Pearce et al., 1982) , even though they did respond weakly only to high concentrations of SP (Ali et al., 1986; Shanahan et al., 1985) . Human mast cells are refractory to the action of 48/80 or polylysine (Lowman et al., 1988b; Church et al., 1982) , while skin mast cells are responsive to these synthetic compounds, as well as to SP, somatostatin and vasoactive intestinal peptide (VIP) (Lowman et al., 1988a,b; Piotrowski & Foreman, 1985) .
Conclusion
The present ®ndings suggest that chondroitin sulphate may be useful as a natural`anti-allergic' agent. In addition, evidence that mast cells are involved in neuroin¯ammatory processes Foreman, 1987; Goetzl et al., 1985; Stead & Bienenstock, 1990; Theoharides, 1996) and are present in in¯amed joints (Crisp et al., 1984; Wasserman, 1984; Metzler & Xu, 1997) , may help explain (Theoharides & Boucher, 1999 ) a meta-analysis suggesting that chondroitin sulphate may be bene®cial in osteoarthritis (McAlindon, et al., 2000) . In fact the US National Institutes of Health recently sponsored a trial (NIH-NIAMS-98-2) to test the ecacy of chondroitin sulphate in osteoarthritis.
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